The impact of age, comorbidity, and current medication use on plasma p-tau217 in adolescents

This study demonstrates that while plasma p-tau217 levels in adolescents remain stable across age, comorbidities, and medication use, they are significantly and discordantly elevated in Tasso+ capillary samples compared to venous plasma, highlighting a critical methodological limitation for decentralized biomarker studies.

The Gist

Imagine your brain is a bustling city. For a long time, scientists have been looking for a specific "smoke signal" in the blood that tells them if the city's infrastructure is crumbling due to Alzheimer's disease. This smoke signal is a molecule called p-tau217. In older adults, finding high levels of this smoke signal is a very reliable warning that the brain's roads (neurons) are getting damaged.

But what about teenagers? Their brains are under heavy construction, constantly remodeling and growing. The big question was: Does the "construction noise" of adolescence look like the "smoke signal" of disease? And, if we ask a teenager to give a blood sample, does it matter how they give it?

Here is what this study found, broken down into simple concepts:

1. The "Construction Site" is Quiet

The researchers wanted to know if common things happening in a teenager's life—like getting older, gaining weight, having anxiety, or taking common medications—would make the "smoke signal" (p-tau217) go up or down.

• The Analogy: Imagine you are trying to hear a whisper in a noisy room. You might worry that the room getting louder (age), the furniture changing (weight), or people talking on phones (medications) would drown out the whisper.
• The Finding: The study found that for teenagers, the "whisper" of p-tau217 is actually very steady. Whether a teen is 10 or 20, has diabetes, has depression, or is taking antidepressants, their levels of this molecule stayed remarkably consistent.
• The Takeaway: In the teenage years, this biomarker is stable. It doesn't get confused by normal life changes or common illnesses. This is great news because it means if we see high levels in a teen later, it's likely a real warning sign, not just a side effect of being a teenager.

2. The "Collection Method" Trap

The second part of the study was a major surprise. The researchers compared two ways of getting blood:

1. The Classic Way: A nurse uses a needle to draw blood from a vein (Venous).
2. The Modern Way: A teenager uses a special wristband-like device (Tasso+) to prick their finger and collect a tiny drop of blood at home (Capillary).

• The Analogy: Imagine you are trying to measure the amount of sugar in a cup of tea.
  • Method A: You carefully dip a spoon into the tea and measure it.
  • Method B: You dip the spoon into the tea, but the spoon is made of a material that accidentally adds 10 extra spoonfuls of sugar just by touching the liquid.
• The Finding: When they used the modern "finger-prick" device (Tasso+), the results were more than 10 times higher than the classic vein draw. It wasn't that the teenagers had more "smoke"; it was that the method of collecting the blood created a false alarm.
• The Takeaway: You cannot compare a finger-prick test to a vein test. They are like measuring with two different rulers that have different scales. If you mix them up, you will get the wrong answer.

Why Does This Matter?

This study is like a "User Manual" for the future of brain health testing in kids.

1. For Doctors: It tells them that if they test a teenager's blood for this Alzheimer's marker, they don't need to worry that the kid's age, weight, or anxiety meds will mess up the results. The test is robust.
2. For Researchers: It sounds a huge warning bell. As science moves toward "decentralized" studies (where people test themselves at home using finger-prick kits), we have to be careful. If we use a finger-prick kit for p-tau217, we might get a result that looks like a disaster, when it's actually just a quirk of the collection device.

In a nutshell:
The "smoke signal" for brain health in teenagers is calm and steady, unaffected by their daily lives. However, the way we catch that smoke matters immensely. If we use the wrong net (the finger-prick device), we might catch a storm that isn't really there. Until we fix the net, we can't compare the two methods.

Technical Summary

1. Problem Statement

Plasma phosphorylated tau at threonine 217 (p-tau217) has emerged as a highly sensitive and specific blood-based biomarker for Alzheimer's Disease (AD) neuropathology in older adults, correlating with amyloid/tau PET burden and CSF markers. However, its behavior during adolescence remains undefined.

• Knowledge Gap: It is unclear whether p-tau217 levels fluctuate due to normal neurodevelopment, common chronic medical conditions (psychiatric, cardiometabolic, gastrointestinal), or long-term medication use in youth.
• Methodological Concern: As decentralized biomarker research grows, there is a need to validate whether capillary blood collection (e.g., via Tasso+ devices) yields comparable results to standard venous phlebotomy for this specific analyte in pediatric populations.

2. Methodology

The study employed a cross-sectional design with two distinct cohorts:

• Adolescent Cohort (Primary Study):

  • Participants: $n=41$ adolescents (ages 10–21; mean age 16 ± 2.6 years) receiving outpatient care at a pediatric academic medical center.
  • Data Collection: Demographics, medical history, and medication use were gathered via self-report and electronic medical records. Participants were categorized by psychiatric, cardiometabolic, and gastrointestinal (GI) comorbidities and corresponding medication use.
  • Sample Processing: Venous blood was collected in EDTA tubes, centrifuged, and stored at -80°C.
  • Assay: Plasma p-tau217 was measured using the Quanterix Simoa HD-X platform with the ALZPath pTau217 Advantage Plus kit. Samples underwent a maximum of two freeze-thaw cycles.
  • Statistical Analysis: Normality was confirmed (Shapiro-Wilk). Correlations (Pearson's $r$) and group differences (Welch's $t$-test) were calculated. Three linear regression models were constructed to adjust for age, sex, BMI z-score, comorbidities, and medication classes.

• Adult Validation Cohort (Methodological Comparison):

  • Participants: 6 healthy adult volunteers.
  • Procedure: Paired samples were collected simultaneously via venipuncture and the Tasso+ capillary collection device.
  • Analysis: Direct comparison of p-tau217 concentrations between the two collection methods.

3. Key Contributions

• Developmental Baseline: Establishes the first reference range for plasma p-tau217 in a diverse adolescent cohort, confirming physiological stability across common clinical variables.
• Methodological Discovery: Identifies a critical, previously unreported discordance between venous and Tasso+ capillary plasma concentrations for p-tau217.
• Clinical Guidance: Provides evidence that common pediatric comorbidities and medications do not confound p-tau217 measurements, supporting its potential use in pediatric neuroscience research (excluding collection method artifacts).

4. Results

A. Clinical Variables in Adolescents

• Age and BMI: No significant correlation was found between p-tau217 levels and age ($r = -0.10, p=0.53$) or BMI z-score ($r = -0.10, p=0.56$).
• Comorbidities: p-tau217 levels did not differ significantly between adolescents with and without:
  • Psychiatric diagnoses (e.g., anxiety, depression, ADHD): $0.23 \pm 0.10$ vs. $0.19 \pm 0.11$ pg/mL ($p=0.28$).
  • Cardiometabolic diagnoses (e.g., diabetes, dyslipidemia): $0.16 \pm 0.06$ vs. $0.23 \pm 0.11$ pg/mL ($p=0.017$, though effect size was moderate and not significant after strict multiple comparison adjustments).
  • GI diagnoses (e.g., GERD): $0.23 \pm 0.11$ vs. $0.19 \pm 0.09$ pg/mL ($p=0.18$).
• Medication Use: No significant differences were observed based on the use of psychiatric, cardiometabolic, or GI medications.
• Regression Models: Linear regression models (adjusted for age, sex, BMI, comorbidities, and meds) showed no significant predictors of p-tau217 levels ($R^2$ values were negative, indicating no explanatory power).

B. Methodological Discordance (Venous vs. Capillary)

• Magnitude of Difference: p-tau217 concentrations in Tasso+ capillary plasma were >10-fold higher than in paired venous plasma.
  • Adolescent subset (Tasso+): $4.51 \pm 1.17$ pg/mL vs. Venous: $0.21 \pm 0.10$ pg/mL.
  • Adult validation (Tasso+): $3.73 \pm 1.58$ pg/mL vs. Venous: $0.40 \pm 0.15$ pg/mL.
• Correlation: There was no significant correlation between paired venous and capillary values ($r = -0.35, p=0.50$), indicating the two methods are not interchangeable.

C. Threshold Analysis

• Using the conservative threshold of 0.40 pg/mL (often used for amyloid positivity in older adults), only 7% ($n=3$) of adolescents exceeded this level.
• Using a lower threshold (0.35 pg/mL) suggested for adults <65, 12% ($n=5$) exceeded the limit, though the clinical significance of "amyloid positivity" in adolescents remains unknown.

5. Significance and Implications

• Physiological Stability: The study confirms that p-tau217 is a stable biomarker in adolescence, unaffected by the common chronic diseases and medications prevalent in this age group. This supports its utility in future pediatric research into psychiatric and neurodevelopmental disorders.
• Critical Methodological Warning: The >10-fold elevation in Tasso+ capillary samples compared to venous samples is a major finding. It suggests that capillary and venous plasma cannot be pooled or directly compared in p-tau217 studies. This has immediate implications for decentralized clinical trials and direct-to-consumer testing (e.g., Neurogen), where capillary sampling is often preferred for ease of use.
• Future Directions: While p-tau217 is stable, the study highlights the need to define whether elevated levels in adolescents (if found) reflect neurodevelopmental processes, early pathology, or are simply artifacts of collection methods. Further research is needed to determine appropriate thresholds for youth and the impact of genetic risk factors (e.g., APOE ε4).

Conclusion: Plasma p-tau217 is a robust, stable biomarker in adolescents regarding clinical comorbidities but is highly sensitive to the blood collection method. Researchers must strictly adhere to venous collection protocols or develop specific correction factors for capillary methods before utilizing p-tau217 in pediatric or decentralized studies.